X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs STRIDES SHASUN LTD - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH STRIDES SHASUN LTD STERLING BIOTECH/
STRIDES SHASUN LTD
 
P/E (TTM) x -0.4 38.4 - View Chart
P/BV x 0.0 1.1 1.3% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 STERLING BIOTECH   STRIDES SHASUN LTD
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
STRIDES SHASUN LTD
Mar-18
STERLING BIOTECH/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs111,147 0.9%   
Low Rs3642 0.5%   
Sales per share (Unadj.) Rs26.8317.2 8.4%  
Earnings per share (Unadj.) Rs-15.07.8 -190.7%  
Cash flow per share (Unadj.) Rs-5.525.1 -21.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs54.9274.3 20.0%  
Shares outstanding (eoy) m267.8789.50 299.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.8 9.2%   
Avg P/E ratio x-0.5114.0 -0.4%  
P/CF ratio (eoy) x-1.335.7 -3.6%  
Price / Book Value ratio x0.13.3 3.9%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m1,86280,058 2.3%   
No. of employees `0001.42.5 54.0%   
Total wages/salary Rs m5474,341 12.6%   
Avg. sales/employee Rs Th5,303.311,325.8 46.8%   
Avg. wages/employee Rs Th403.81,731.4 23.3%   
Avg. net profit/employee Rs Th-2,959.0280.1 -1,056.6%   
INCOME DATA
Net Sales Rs m7,18128,394 25.3%  
Other income Rs m43941 4.5%   
Total revenues Rs m7,22329,334 24.6%   
Gross profit Rs m9473,965 23.9%  
Depreciation Rs m2,5431,540 165.1%   
Interest Rs m4,3771,962 223.0%   
Profit before tax Rs m-5,9311,403 -422.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m-1,92497 -1,977.7%   
Profit after tax Rs m-4,007702 -570.6%  
Gross profit margin %13.214.0 94.4%  
Effective tax rate %32.46.9 467.9%   
Net profit margin %-55.82.5 -2,256.4%  
BALANCE SHEET DATA
Current assets Rs m14,33524,836 57.7%   
Current liabilities Rs m49,80918,993 262.3%   
Net working cap to sales %-494.020.6 -2,400.7%  
Current ratio x0.31.3 22.0%  
Inventory Days Days40371 568.4%  
Debtors Days Days171113 150.5%  
Net fixed assets Rs m55,43234,289 161.7%   
Share capital Rs m268895 29.9%   
"Free" reserves Rs m13,93523,651 58.9%   
Net worth Rs m14,70124,546 59.9%   
Long term debt Rs m9,47815,513 61.1%   
Total assets Rs m73,98865,437 113.1%  
Interest coverage x-0.41.7 -20.7%   
Debt to equity ratio x0.60.6 102.0%  
Sales to assets ratio x0.10.4 22.4%   
Return on assets %0.54.1 12.3%  
Return on equity %-27.32.9 -952.8%  
Return on capital %-6.46.9 -93.2%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86015,697 11.8%   
Fx outflow Rs m25735 3.4%   
Net fx Rs m1,83514,962 12.3%   
CASH FLOW
From Operations Rs m1,7191,871 91.9%  
From Investments Rs m-3,1485,826 -54.0%  
From Financial Activity Rs m1,426-10,157 -14.0%  
Net Cashflow Rs m-3-2,615 0.1%  

Share Holding

Indian Promoters % 33.9 27.7 122.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 37.8 -  
FIIs % 9.9 8.6 115.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 25.9 151.7%  
Shareholders   21,482 56,241 38.2%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

STRIDES SHASUN LTD Announces Quarterly Results (4QFY18); Net Profit Down 99.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, STRIDES SHASUN LTD has posted a net profit of Rs 8 m (down 99.2% YoY). Sales on the other hand came in at Rs 7 bn (down 25.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Oct 15, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - IPCA LABS COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS